In a patient with acute non‑variceal upper gastrointestinal bleeding who has required transfusion and undergone endoscopic therapy for a high‑risk lesion, should pantoprazole be given as a continuous intravenous infusion (drip) or as intermittent intravenous pushes?

Pantoprazole Administration in High-Risk Non-Variceal Upper GI Bleeding

For patients with acute non-variceal upper GI bleeding requiring transfusion who have undergone endoscopic therapy for high-risk lesions, use pantoprazole as an 80 mg IV bolus followed by continuous infusion at 8 mg/hour for 72 hours. This is the guideline-recommended regimen that should be followed 1, 2, 3.

Guideline Recommendations

The international consensus guidelines explicitly recommend high-dose PPI therapy as an intravenous loading dose followed by continuous infusion for patients with bleeding ulcers with high-risk stigmata (active bleeding, visible vessel, or adherent clot) who have had successful endoscopic therapy 1. The ESGE 2021 guidelines similarly recommend this approach: 80 mg bolus then 8 mg/hour continuous infusion for 72 hours post-endoscopy 3. The WSES guidelines also suggest administration of high-dose PPI as continuous infusion for the first 72 hours after successful endoscopic hemostasis 2.

FDA-Approved Dosing

The FDA label for pantoprazole supports both administration methods but specifies different indications 4:

• For GERD with erosive esophagitis: 40 mg once daily (can be given as 15-minute infusion or 2-minute push)
• For pathological hypersecretion (Zollinger-Ellison): 80 mg every 12 hours

Importantly, the FDA label explicitly states that "Pantoprazole Sodium for Injection 40 mg once daily does not raise gastric pH to levels sufficient to contribute to the treatment of such life-threatening conditions" as upper GI bleeds 4. This directly contradicts using intermittent dosing for high-risk bleeding.

Research Evidence Context

While several studies suggest intermittent dosing may be non-inferior to continuous infusion 5, 6, 7, these findings have not been incorporated into major international guidelines. The 2014 meta-analysis by Sachar et al. showed intermittent PPI therapy was comparable to continuous infusion (risk ratio 0.72, absolute risk difference -2.64%) 5. However, this research has not changed the standard of care recommended by guideline bodies.

Critical Distinction

The key issue is timing relative to endoscopy:

• Post-endoscopy in high-risk lesions: Guidelines mandate continuous infusion 1, 2, 3
• Pre-endoscopy or lower-risk situations: Some flexibility exists for intermittent dosing 8

Your scenario specifically describes a patient who has already undergone endoscopic therapy for a high-risk lesion and required transfusion—this is the exact population for whom continuous infusion is recommended.

Practical Implementation

1. Immediate: Give 80 mg pantoprazole IV bolus
2. Continuous infusion: Start 8 mg/hour (80 mg in 100 mL over ~10 hours, then repeat) for 72 hours total
3. After 72 hours: Transition to oral PPI 40 mg twice daily through day 14, then once daily 1

Common Pitfalls

• Do not substitute intermittent dosing in this high-risk, post-endoscopy population despite research suggesting equivalence—guidelines have not changed
• Do not use 40 mg once daily dosing for acute bleeding—this is insufficient for life-threatening hemorrhage per FDA labeling 4
• Do not rely solely on cost considerations to deviate from guideline-recommended continuous infusion in this high-risk scenario, as this prioritizes morbidity and mortality outcomes

The continuous infusion regimen remains the standard of care endorsed by international guidelines for your specific clinical scenario 1, 2, 3.